XueZhiKang
Phase 3Small molecule
Luye Pharma Group Ltd.XueZhiKang is one of 5 small molecule programs targeting Dyslipidemia. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Dyslipidemia
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
XueZhiKang
Luye Pharma Group Ltd.Phase 3
AZD4954
AstraZenecaPhase 1
HRS-5632
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
Pueraria Lobata
JJiangxi University of Traditional Chinese Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dyslipidemia3 trials
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
Completed·—·Phase 4·NCT05238012·392 enrolled
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
Recruiting·—·Phase 4·NCT06750783·398 enrolled
Hypertensive1 trial
Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients
Unknown status·—·Phase 4·NCT02254824·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XueZhiKang. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company